Klaus Langer

Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.

Hagen von Briesen, H. von Briesen, J. Kreuter, 2005, Biomaterials.

Photosensitizer loaded HSA nanoparticles II: in vitro investigations.

Matthias G. Wacker, Steffen Hackbarth, Beate Röder, 2011, International journal of pharmaceutics.

Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.

Sylvia Wagner, Hagen von Briesen, H. von Briesen, 2008, Bioconjugate chemistry.

Serum type and concentration both affect the protein-corona composition of PLGA nanoparticles

Hans-Ulrich Humpf, H. Humpf, K. Langer, 2019, Beilstein journal of nanotechnology.

Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties.

Matthias Wacker, Annegret Preuss, A. Preuß, 2010, International journal of pharmaceutics.

Highly Specific HER2-mediated Cellular Uptake of Antibody-modified Nanoparticles in Tumour Cells

K. Strebhardt, J. Kreuter, K. Langer, 2004, Journal of drug targeting.

Characterization of serum albumin nanoparticles by sedimentation velocity analysis and electron microscopy

Vitali Vogel, Peter Schuck, V. Vogel, 2002 .

Comparison of cellular effects of starch-coated SPIONs and poly(lactic-co-glycolic acid) matrix nanoparticles on human monocytes

Harald Fuchs, Kristina Riehemann, Guiscard Seebohm, 2016, International journal of nanomedicine.